Vaccitech has appointed Bill Enright as its new Chief Executive Officer. Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.   Bill joins Vaccitech after an accomplished 11 years as CEO at Gaithersburg-based Altimmune Inc., where he led Altimmune through a significant period of growth including a Series B financing, the acquisition of Immune Targeting Systems – a UK T-cell vaccine company – and taking the compan...